Literature DB >> 18423948

A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

Perrine Martin1, Benjamin Simon, Yu-Chun Lone, Laurence Chatel, Ronald Barry, Geneviève Inchauspé, Anne Fournillier.   

Abstract

Multiepitope-based vaccines against hepatitis C virus (HCV) were designed in the form of three minigenes encompassing four domains of the NS3, NS4 and NS5B proteins that contain multiple class I/II restricted epitopes. The polyEp-WT minigene encodes all four domains in fusion, the polyEp-C minigene encodes the same fusion but optimised for mammalian translation and the polyEp-E3 minigene has an additional endoplasmic reticulum targeting sequence. Whereas the minigenes vectorised by DNA were poorly immunogenic, adenovirus vectorisation induced strong and broader IFNgamma-ELISpot and CTL responses in HLA-A2 transgenic mice. In addition, polyEp-WT and polyEp-E3 responses were found cross-reactive in a recombinant Listeria-NS3-based surrogate challenge. This study illustrates the potency of vectorised minigenes in the field of HCV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423948     DOI: 10.1016/j.vaccine.2008.03.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

2.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

3.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

Review 4.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.

Authors:  Marian E Major
Journal:  Viruses       Date:  2009-08-12       Impact factor: 5.048

6.  Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.

Authors:  Jie Guan; Bo Wen; Yao Deng; Ke Zhang; Hong Chen; Xiaobing Wu; Li Ruan; Wenjie Tan
Journal:  Virol J       Date:  2011-11-04       Impact factor: 4.099

7.  Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice.

Authors:  Leila Pishraft Sabet; Tahereh Taheri; Arash Memarnejadian; Talat Mokhtari Azad; Fatemeh Asgari; Ramin Rahimnia; Seyed Moayed Alavian; Sima Rafati; Katayoun Samimi Rad
Journal:  Hepat Mon       Date:  2014-10-15       Impact factor: 0.660

8.  Hepatitis C virus DNA vaccines: a systematic review.

Authors:  Ali Shayeghpour; Roya Kianfar; Parastoo Hosseini; Mehdi Ajorloo; Sepehr Aghajanian; Mojtaba Hedayat Yaghoobi; Tayebeh Hashempour; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2021-12-13       Impact factor: 4.099

9.  Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Authors:  Yong-Chen Lu; Xin Yao; Jessica S Crystal; Yong F Li; Mona El-Gamil; Colin Gross; Lindy Davis; Mark E Dudley; James C Yang; Yardena Samuels; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

10.  Sequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds.

Authors:  Nishi Prabdial-Sing; Adrian J Puren; Sheila M Bowyer
Journal:  BMC Immunol       Date:  2012-12-10       Impact factor: 3.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.